NIKKEI 225
38,079.70 +117.90 (+0.31%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.58 -0.15 (-0.18%) GOLD FUTURES
2,395.10 -2.90 (-0.12%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,081.24 +1,773.18 (+3.60%)
Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 66.93 |
| Open | 67.01 |
| Bid | 66.13 x 500 |
| Ask | 66.17 x 300 |
| Day's range | 65.90 - 67.01 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,420,538 |
| Market cap | 82.5B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.70 |
| EPS (TTM) | 4.50 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.60%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 79.65 |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ZacksAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
